Lupin announced the launch of Bromfenac Ophthalmic Solution, 0.075%, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Bromfenac Ophthalmic Solution, 0.075% is a generic equivalent of BromSite Ophthalmic Solution, 0.075%, of Sun Pharmaceutical Industries Limited. It is indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.

Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S. (IQVIA MAT December 2023).